Gabelli Funds LLC reduced its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 12.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 721,387 shares of the biopharmaceutical company’s stock after selling 106,000 shares during the period. Gabelli Funds LLC’s holdings in Bristol-Myers Squibb were worth $44,207,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after purchasing an additional 333,685 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after acquiring an additional 2,367,864 shares during the last quarter. Dodge & Cox lifted its holdings in shares of Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after acquiring an additional 459,271 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after acquiring an additional 3,735,453 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Bristol-Myers Squibb by 3.9% during the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after buying an additional 910,496 shares during the period. Institutional investors and hedge funds own 71.55% of the company’s stock.
Shares of Bristol-Myers Squibb Co (BMY) traded down $0.33 during trading hours on Wednesday, hitting $66.35. 3,312,683 shares of the company were exchanged, compared to its average volume of 7,973,780. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a fifty-two week low of $51.56 and a fifty-two week high of $70.05. The company has a market capitalization of $109,420.00, a price-to-earnings ratio of 28.09, a PEG ratio of 2.07 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. analysts forecast that Bristol-Myers Squibb Co will post 3.2 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is 67.80%.
BMY has been the topic of a number of recent analyst reports. ValuEngine downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research report on Thursday, March 8th. Bank of America increased their price target on shares of Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a research note on Monday, March 5th. Jefferies Group set a $72.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, February 26th. Finally, DZ Bank cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $66.30.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.23% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Gabelli Funds LLC Reduces Stake in Bristol-Myers Squibb Co (BMY)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/03/14/gabelli-funds-llc-has-44-21-million-stake-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.